ArticleCommunications biology2020
IDO1
Open access · goldAbstract read
In one paragraph
Article in Communications biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 37 citations in OpenAlex.
- Immune evasion in locally advanced mismatch repair-deficient microsatellite instability-high colorectal cancer: Reduced T-cell infiltration and upregulation of epithelial IDO1 expression.Oncoimmunology · 2026Article
- Differential Effects of Saturated and Unsaturated Fatty Acids on Colorectal Cancer via IDO1 Signaling.Cancer medicine · 2026Article
- Review
- Colorectal cancer prognosis: insights from the tumor immune microenvironment and gut microbiota.Journal of gastrointestinal oncology · 2025Article
- Radiation-Enhanced AF1q Moves Center Stage as a Key Driver to Favorable Tumor Stage in Rectal Cancer Patients.Cancer medicine · 2025Article
- Dual regulation of gastrointestinal tumor progression by the IFN-γ/STAT1 pathway and prospects for targeted therapy.Frontiers in oncology · 2025Review
- Metastasis of colon cancer requires Dickkopf-2 to generate cancer cells with Paneth cell properties.eLife · 2024Article
- Article
- Metastasis of colon cancer requires Dickkopf-2 to generate cancer cells with Paneth cell properties.bioRxiv : the preprint server for biology · 2024Article
- The emerging roles of deep crypt secretory cells in colonic physiology.American journal of physiology. Gastrointestinal and liver physiology · 2023Review
- Tumor microenvironment characterization in colorectal cancer to identify prognostic and immunotherapy genes signature.BMC cancer · 2023Article
- Interplay between Signaling Pathways and Tumor Microenvironment Components: A Paradoxical Role in Colorectal Cancer.International journal of molecular sciences · 2023Review
- Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model.Frontiers in oncology · 2023Article
- Intestinal Stem Cells Damaged by Deoxycholic Acid via AHR Pathway Contributes to Mucosal Barrier Dysfunction in High-Fat Feeding Mice.International journal of molecular sciences · 2022Article
- Intestinal epithelial cell metabolism at the interface of microbial dysbiosis and tissue injury.Mucosal immunology · 2022Review
- Changing Metabolic Patterns along the Colorectal Adenoma-Carcinoma Sequence.Journal of clinical medicine · 2022Article
- Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.Drug design, development and therapy · 2022Review
- Tyk2 is a tumor suppressor in colorectal cancer.Oncoimmunology · 2022Article
- PersistentMicroorganisms · 2021Article
- Role of immune escape in different digestive tumours.World journal of clinical cases · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 7 institutions in 4 countries.
Sandra Pflügler *Institute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Jasmin Svinka *Institute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Irene ScharfInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Ilija CrncecInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Martin FilipitsInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0003-2847-4534
Pornpimol CharoentongInstitute of Bioinformatics, Medical University Innsbruck, Biocenter, 6020, Innsbruck, Austria.
Markus TschurtschenthalerDivision of Gastroenterology and Hepatology, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK.ORCID http://orcid.org/0000-0002-0060-4790
Lukas KennerLudwig Boltzmann Institute for Cancer Research LBICR, 1090, Vienna, Austria.
Monira AwadInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Judith StiftInstitute of Clinical Pathology, Medical University of Vienna, 1090, Vienna, Austria.
Marina SchernthannerInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Romana BischlInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Dietmar Herndler-BrandstetterInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Elisabeth GlitznerInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Herwig P MollDepartment of Physiology, Center of Physiology and Pharmacology, Comprehensive Cancer Center (CCC), Medical University of Vienna, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0001-6438-9068
Emilio CasanovaLudwig Boltzmann Institute for Cancer Research LBICR, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0001-7992-5361
Gerald TimelthalerInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Maria SibiliaInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Michael GnantDepartment of Surgery, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0003-1002-2118
Sigurd LaxDepartment of Pathology, Hospital Graz II, 8020, Graz, Austria.
Josef ThalerDepartment of Internal Medicine IV, Klinikum Wels-Grieskirchen, 4600, Wels, Austria.
Mathias MüllerInstitute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210, Vienna, Austria.ORCID http://orcid.org/0000-0002-7879-3552
Birgit StroblInstitute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210, Vienna, Austria.ORCID http://orcid.org/0000-0001-5716-3212
Thomas MohrInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0002-1933-847X
Arthur KaserDivision of Gastroenterology and Hepatology, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK.
Zlatko TrajanoskiInstitute of Bioinformatics, Medical University Innsbruck, Biocenter, 6020, Innsbruck, Austria.ORCID http://orcid.org/0000-0002-0636-7351
Gerwin HellerDivision of Oncology, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria.
Robert EferlInstitute of Cancer Research, Medical University of Vienna and Comprehensive Cancer Center, 1090, Vienna, Austria. robert.eferl@meduniwien.ac.at.ORCID http://orcid.org/0000-0002-6074-7144
Comprehensive Cancer Center Vienna · ATUniversity of Veterinary Medicine Vienna · ATInnsbruck Medical University · ATUniversity of Cambridge · GBJohannes Kepler University of Linz · ATKlinikum Wels-Grieskirchen · ATMedical University of Vienna · AT
Funding
Austrian Science Fund FWF F4709-B20Austrian Science Fund FWF P 26011Austrian Science Fund FWF P 29222Austrian Science Fund FWF P29222-B28Austrian Science Fund FWF P 32900Austrian Science Fund FWF SFB F6106Austrian Science Fund FWF W1212-P21
Abstract
Tumors have evolved mechanisms to escape anti-tumor immunosurveillance. They limit humoral and cellular immune activities in the stroma and render tumors resistant to immunotherapy. Sensitizing tumor cells to immune attack is an important strategy to revert immunosuppression. However, the underlying mechanisms of immune escape are still poorly understood. Here we discover Indoleamine-2,3-dioxygenase-1 (IDO1)
Indexed as
AnimalsColorectal NeoplasmsImmune ToleranceIndoleamine-Pyrrole 2,3,-DioxygenaseIntestinal NeoplasmsMaleMiceMice, Inbred C57BLMice, KnockoutPaneth CellsSTAT1 Transcription FactorIndoleamine-Pyrrole 2,3,-DioxygenaseSTAT1 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.